

I hereby certify that this correspondence is being filed via  
EFS-Web with the United States Patent and Trademark Office  
on October 31, 2007.

TOWNSEND and TOWNSEND and CREW LLP

By: /Nina L. McNeill/  
Nina L. McNeill

**AMENDMENT UNDER 37 CFR 1.116  
EXPEDITED PROCEDURE –  
EXAMINING GROUP 1632**

**PATENT**

Attorney Docket No.: 016930-003712US  
Client Ref. No.: CJ01661

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Nielsen et al.

Application No.: 10/086,294

Filed: February 28, 2002

For: COMBINED TUMOR  
SUPPRESSOR GENE THERAPY AND  
CHEMOTHERAPY IN THE  
TREATMENT OF NEOPLASMS

Customer No.: 20350

Confirmation No. 3210

Examiner: Joanne Hama

Technology Center/Art Unit: 1632

**AMENDMENT UNDER 37 CFR 1.116  
EXPEDITED PROCEDURE EXAMINING  
GROUP 1632**

Mail Stop AF  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Final Office Action mailed September 19, 2007 on the above-referenced application, please enter the following amendments and remarks:

**Amendments to the Claims** are reflected in the listing of claims which begins on page 2 of this paper.

**Remarks/Arguments** begin on page 8 of this paper.